Vanderbilt University
Publishes on Neuroendocrine Tumor Research Advances, Gout, Hyperuricemia, Uric Acid, Cancer therapeutics and mechanisms. 3 papers and 874 citations.
Add your photo, update your bio, and get notified when your ranking changes.
Plasma urine, and cerebrospinal fluid etoposide concentrations have been measured in 12 adult patients after administration of high-dose (400 to 800 mg/sq m) etoposide in order to determine the pharmacokinetics of this drug at these elevated dosages. Increasing the drug dosage produced proportionally higher peak plasma etoposide concentrations (27 to 114 micrograms/ml) and total areas under the concentration-time curve (9,200 to 48,000 micrograms/ml X min). The etoposide mean (+/- S.D.) terminal half-life of 8.05 +/- 4.3 hr and plasma clearance of 28.0 +/- 9.7 ml/min/sq m, however, were independent of the dosage given. The mean etoposide renal clearance in 5 patients was 10.0 +/- 4.3 ml/min/sq m, representing from 35 to 40% of the total clearance of this drug from plasma. Cerebrospinal fluid etoposide concentrations ranged from 0.1 to 1.4 micrograms/ml, as measured in 6 patients at 1 to 8 hr after high-dose etoposide therapy, and were 1.8 +/- 1.7% of the simultaneously measured plasma levels. Pleural fluid removed from one patient at 18 hr posttherapy contained etoposide at 1.8 micrograms/ml. Our data, combined with data published previously, indicate that the pharmacokinetics of high-dose etoposide is linear within the dosage range tested and similar to that seen with lower drug doses. They also suggest that etoposide penetrates poorly into the cerebrospinal fluid.
No AccessJournal of UrologyMiscellaneous1 Jun 1984Severe Allopurinol Toxicity. Description and Guidelines for Prevention in Patients With Renal Insufficiency K.R. Hande, R.M. Noone, and W.J. Stone K.R. HandeK.R. Hande , R.M. NooneR.M. Noone , and W.J. StoneW.J. Stone View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)50916-7AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Severe Allopurinol Toxicity. Description and Guidelines for Prevention in Patients With Renal Insufficiency." The Journal of Urology, 131(6), pp. 1258–1259 © 1984 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 131Issue 6June 1984Page: 1258-1259 Advertisement Copyright & Permissions© 1984 by The American Urological Association Education and Research, Inc.MetricsAuthor Information K.R. Hande More articles by this author R.M. Noone More articles by this author W.J. Stone More articles by this author Expand All Advertisement PDF DownloadLoading ...